Global Immune Checkpoint Inhibitors Market 2019-2023

The immune checkpoint inhibitors market size will grow by USD 24.14 billion during 2019-2023. This report offers an analysis of the market based on type (PD-1 inhibitors, CTLA-4 inhibitors, and others) and geography (Americas, APAC, and EMEA). The immune checkpoint inhibitors market research report further analyzes the market’s competitive landscape and offers information on several companies including AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck Sharp & Dohme, and Pfizer.

Below are some of the key findings from the immune checkpoint inhibitors market research report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Get a FREE sample now!

Global immune checkpoint inhibitors industry overview

The high target affinity and specificity of immune checkpoint inhibitor drugs is one of the primary factors propelling the immune checkpoint inhibitors market growth. Most of the approved therapies for cancer treatment have severe side effects, which lowers patient compliance towards the treatment. Chemotherapy causes adverse side effects such as bone marrow suppression, diarrhea, and alopecia. Similarly, radiation and surgery are known to have limitations over recurrent cancer. Immune checkpoint inhibitors work directly on the target, making them more effective than conventional treatments. They also work by boosting the immune system, thereby reducing side effects on patients. The target-specific mode of action and lower side effects are making immune checkpoint inhibitor drugs a favorite among both medical practitioners and patients. Although this is a relatively new therapy, immune checkpoint inhibitors market is expected to grow substantially during the forecast period.

The expansion of research areas of immune checkpoint inhibitors is among the crucial immune checkpoint inhibitors market trends that will further boost the market. At present, there are seven immune checkpoint inhibitors as monotherapy, and two more combinations were approved for the treatment of various cancers. Due to their high target affinity and specificity, several companies are research on more than 20 different types of cancers using immune checkpoint inhibitors. Additionally, more than a thousand clinical trials are being carried out on several cancers globally. Such expansion in research areas of immune checkpoint inhibitors will impact the market positively. The immune checkpoint inhibitors market report predicts that fueled by these factors, the market will grow at a CAGR of over 19% during the next five years.

Top immune checkpoint inhibitors companies covered in this market research report

The immune checkpoint inhibitors market is moderately concentrated and in the growth phase. Industry experts predict new market entrants are expected, offering cancer treatment with the help of immune checkpoint inhibitors drugs and therapeutics, thereby making the market landscape fragmented. By providing a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this immune checkpoint inhibitors industry analysis report will aid clients to identify and design new growth strategies.

The report offers a complete analysis of various companies including:

• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Pfizer

Immune checkpoint inhibitors market segmentation based on geographic regions

• Americas
• APAC
• EMEA

According to global immune checkpoint inhibitors market analysis, the Americas will lead the immune checkpoint inhibitors market share over the next couple of years. Whereas, the APAC region will account for the highest immune checkpoint inhibitors market growth when compared to other regions globally.

Immune checkpoint inhibitors market segmentation based on inhibitor types

• PD-1 inhibitors
• CTLA-4 inhibitors
• Others

The PD-1 inhibitors will dominate the immune checkpoint inhibitors market share. Other inhibitors, including PD-L1 and PD-L2, will collectively account for the highest immune checkpoint inhibitors market growth. Additionally, the report also provides an accurate prediction of the contribution of the various inhibitor types to the growth of the immune checkpoint inhibitors market size.

Key highlights of the global immune checkpoint inhibitors market for the forecast years 2019-2023:

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the immune checkpoint inhibitors market during the next five years
• Precise estimation of the global immune checkpoint inhibitors market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the immune checkpoint inhibitors industry across the Americas, APAC, and EMEA
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on the factors that will challenge the growth of immune checkpoint inhibitors companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch